VBI Vaccines Inc. (VBIV): The Stock the Top Fund Managers Love

VBI Vaccines Inc. (NASDAQ:VBIV) reached 45.61% versus a 1-year low price of $1.14. The stock was last seen 7.1% higher, reaching at $1.66 on 01/11/2019. At recent session, the prices were hovering between $1.54 and $1.7. This company shares are 396.99% off its target price of $8.25 and the current market capitalization stands at $161.59M. The recent change has given its price a -0.57% deficit over SMA 50 and -63.52% deficit over its 52-week high. The stock witnessed 7.1% gains, -20.95% declines and -42.56% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VBIV’s volatility during a week at 9.21% and during a month it has been found around 11.27%.

VBI Vaccines Inc. (VBIV) Top Holders

Institutional investors currently hold around $49 million or 52.38% in VBIV stock. Look at its top three institutional owners. Perceptive Advisors Llc owns $16.05 million in VBI Vaccines Inc., which represents roughly 9.93% of the company’s market cap and approximately 32.74% of the institutional ownership. Similar statistics are true for the second largest owner, Menora Mivtachim Holdings Ltd., which owns 3,459,868 shares of the stock are valued at $5.74 million. The third largest holder is Bvf Inc/Il, which currently holds $5.15 million worth of this stock and that ownership represents nearly 3.18% of its market capitalization.

VBI Vaccines Inc. 13F Filings

At the end of September reporting period, 11 institutional holders increased their position in VBI Vaccines Inc. (NASDAQ:VBIV) by some 286,823 shares, 21 decreased positions by 1,604,833 and 18 held positions by 27,684,877. That puts total institutional holdings at 29,576,533 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 86,275 shares while 12 institutional investors sold out their entire positions totaling 625,917 shares.

VBI Vaccines Inc. (NASDAQ:VBIV) Insider Trades

Multiple company employees have indulged in significant insider trading. VBI Vaccines Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Kariv Tomer has acquired 1,428,571 shares of VBI Vaccines Inc. (VBIV) in trading session dated Dec. 17, 2018. These shares are worth $1,999,999 and were traded at $1.4 each. The SEC filing shows that Perceptive Life Sciences Maste performed a purchase of 14,285,714 shares. The 10% Owner added these shares by way of transaction on Dec. 13, 2018. The company’s shares were assimilated at $1.4 per share worth to an investment of some $20,000,000 on account of Perceptive Life Sciences Maste.

CEO, President, Baxter Jeff, purchased 8,100 common shares of VBI Vaccines Inc. (VBIV) in the open market. In a transaction dated Aug. 06, 2018, the shares were bought at an average price of $1.93, giving away a sum of $15,633. After this purchase, 233,005 common shares of VBIV are directly owned by the insider, with total stake valued at $386,788.

In the transaction dated Aug. 03, 2018, the great number of shares acquired came courtesy the Chief Medical Officer; Diaz-Mitoma Francisco added a total of 9,000 shares at an average price of $2.13, amounting to approximately $19,170. The insider now directly owns 305,743 shares worth $507,533.

VBI Vaccines Inc. (VBIV) Analyst Guide

Several analysts have released their opinion on VBI Vaccines Inc. (NASDAQ:VBIV), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.6 average brokerage recommendation.